Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

Metronomic chemotherapy, continuous and dose‐dense administration of chemotherapeutic
drugs with lowered doses, is being evaluated for substituting, augmenting, or appending …

Although survival of multiple myeloma patients has at least doubled during recent years,
most patients eventually relapse, and treatment at this stage may be particularly complex. At …

Multiple myeloma remains an incurable disease with the usual disease course requiring
induction therapy, autologous stem cell transplantation for eligible patients, and long-term …

Despite recent advances, multiple myeloma remains an incurable disease for most patients,
and initial remission will be followed by relapses requiring therapy. For many, there will be …

Abstract Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line
imaging modality for bone disease assessment in patients with plasma cell disorders and …

Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …

Over the last years, there has been great progress in the treatment of multiple myeloma with
many new agents and combinations having been approved and being now routinely …

From the 1960s to the early 2000s, alkylating agents (eg, melphalan, cyclophosphamide,
and bendamustine) remained a key component of standard therapy for newly-diagnosed or …